Featured Publications
Full facial retransplantation in a female patient—Technical, immunologic, and clinical considerations
Kauke M, Panayi AC, Safi A, Haug V, Perry B, Kollar B, Nizzi M, Broyles J, Annino DJ, Marty FM, Sinha I, Lian CG, Murphy GF, Chandraker A, Pomahac B. Full facial retransplantation in a female patient—Technical, immunologic, and clinical considerations. American Journal Of Transplantation 2021, 21: 3472-3480. PMID: 34033210, DOI: 10.1111/ajt.16696.Peer-Reviewed Original ResearchMeSH KeywordsComposite Tissue AllograftsFemaleGraft RejectionHumansReoperationTransplantation, HomologousConceptsChronic antibody-mediated rejectionPatient underwent retransplantationRecurrent cellular rejectionAntibody-mediated rejectionImmediate postoperative phaseInterposition vein graftAllograft lossCellular rejectionFirst allograftOlder allograftsRejection episodesUnderwent retransplantationSecond transplantationFirst transplantPostoperative outcomesAllotransplant recipientsPostoperative phaseVein graftsHyperacute rejectionFacial nerveOutcomes 6Arterial anastomosisRetransplantationSurgical techniquePsychosocial managementFace Transplantation in a Black Patient — Racial Considerations and Early Outcomes
Kauke M, Panayi AC, Tchiloemba B, Diehm YF, Haug V, Kollar B, Perry B, Singhal D, Sinha I, Riella LV, Annino DJ, Pomahac B. Face Transplantation in a Black Patient — Racial Considerations and Early Outcomes. New England Journal Of Medicine 2021, 384: 1075-1076. PMID: 33730460, PMCID: PMC8182672, DOI: 10.1056/nejmc2033961.Peer-Reviewed Original Research
2024
Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions
Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R, Sherwani K, Ettl T, Mayer S, Falkner F, Kilian K, Panayi A, Iske J, Safi A, Tullius S, Haykal S, Pomahac B, Kauke-Navarro M. Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Frontiers In Immunology 2024, 15: 1372862. PMID: 38650942, PMCID: PMC11033354, DOI: 10.3389/fimmu.2024.1372862.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell- and Tissue-Based TherapyGraft RejectionHumansImmunomodulationOrgan TransplantationConceptsRegulatory myeloid cellsSolid organ transplantationVascularized composite allotransplantationMesenchymal stromal cellsT cellsTransplant patientsCellular therapyChimeric antigen receptor T cellsTransplant surgerySide effectsIncreased risk of malignancyProgression to chronic rejectionAcute rejection ratesPerioperative treatment strategiesRegulatory T cellsPromote immune toleranceRisk of malignancySystemic side effectsRelated side effectsCell typesImprove transplant survivalCAR-TCell therapy applicationsImmunosuppressive regimensChronic rejection
2023
Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation
Kauke-Navarro M, Noel O, Knoedler L, Knoedler S, Panayi A, Stoegner V, Huelsboemer L, Pomahac B. Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation. Journal Of Surgical Research 2023, 291: 176-186. PMID: 37429217, DOI: 10.1016/j.jss.2023.04.028.Peer-Reviewed Original ResearchConceptsImmunosuppressive regimensAllograft rejectionComposite allotransplantationDonor-derived immune cellsDonor-derived T lymphocytesRecipient-derived T cellsPotent immunosuppressive regimensToxic immunosuppressive regimensSolid organ transplantationAntigen-presenting cellsSystemic side effectsVascularized Composite AllotransplantationCD40 knockoutChronic rejectionRejection episodesSystemic immunosuppressionMost patientsImmunomodulatory strategiesTolerance inductionImmune cellsOrgan transplantationT cellsT lymphocytesSide effectsClinical successCellular activation pathways and interaction networks in vascularized composite allotransplantation
Knoedler L, Knoedler S, Panayi A, Lee C, Sadigh S, Huelsboemer L, Stoegner V, Schroeter A, Kern B, Mookerjee V, Lian C, Tullius S, Murphy G, Pomahac B, Kauke-Navarro M. Cellular activation pathways and interaction networks in vascularized composite allotransplantation. Frontiers In Immunology 2023, 14: 1179355. PMID: 37266446, PMCID: PMC10230044, DOI: 10.3389/fimmu.2023.1179355.Peer-Reviewed Original ResearchConceptsVascularized Composite AllotransplantationComposite allotransplantationRecipient-derived lymphocytesTreatment of patientsCellular activation pathwaysMultidrug immunosuppressionVCA graftsVCA patientsVCA rejectionGraft rejectionDevastating injuriesClinical managementNovel therapiesReconstructive surgeryLimb lossRejection responseFacial disfigurementAllotransplantationPatientsGraftActivation pathwayTissue cellsDifferent cell typesTissue typesCell typesCorrelation between facial vascularized composite allotransplantation rejection and laboratory markers: Insights from a retrospective study of eight patients
Kauke-Navarro M, Knoedler S, Panayi A, Knoedler L, Haller B, Parikh N, Huelsboemer L, Stoegner V, Kiefer J, Eisenhardt S, Azzi J, Pomahac B. Correlation between facial vascularized composite allotransplantation rejection and laboratory markers: Insights from a retrospective study of eight patients. Journal Of Plastic Reconstructive & Aesthetic Surgery 2023, 83: 155-164. PMID: 37276734, DOI: 10.1016/j.bjps.2023.04.050.Peer-Reviewed Original ResearchInsights from immunoproteomic profiling of a rejected full-face transplant
Lee C, Wang D, Kauke-Navarro M, Russell-Goldman E, Xu S, Mucciarone K, Sohrabi S, Lian C, Pomahac B, Murphy G. Insights from immunoproteomic profiling of a rejected full-face transplant. American Journal Of Transplantation 2023, 23: 1058-1061. PMID: 37037378, DOI: 10.1016/j.ajt.2023.04.008.Peer-Reviewed Original ResearchConceptsVascularized Composite AllograftsT cellsChronic rejectionCD8-positive T cellsEffector T cellsFull face transplantArteriosclerotic alterationsIntragraft arteriesVCA rejectionGraft arteryAccelerated arteriosclerosisRecipient originPunch biopsyAtherogenic responseComposite allograftsImmunoproteomic profilingDioxygenase 1Target endotheliumArteryEndotheliumProteomic profilingPathway componentsCellsRejectionAllograftsTolerance Induction in Vascularized Composite Allotransplantation—A Brief Review of Preclinical Models
Huelsboemer L, Kauke-Navarro M, Reuter S, Stoegner V, Feldmann J, Hirsch T, Kueckelhaus M, Dermietzel A. Tolerance Induction in Vascularized Composite Allotransplantation—A Brief Review of Preclinical Models. Transplant International 2023, 36: 10955. PMID: 36846605, PMCID: PMC9946984, DOI: 10.3389/ti.2023.10955.Peer-Reviewed Original ResearchConceptsTolerance inductionLong-term effectsAnimal modelsImmune systemDonor-specific toleranceLong-term outcomesRecipient's immune systemPreclinical animal modelsNovel therapeutic strategiesPre-clinical studiesVascularized Composite AllotransplantationChronic rejectionImmunosuppressive protocolsTransplant recipientsAllograft rejectionOrgan dysfunctionPreclinical modelsComposite allograftsTherapeutic strategiesComposite allotransplantationClinical practiceIS protocolClinical translationInductionReview article
2022
Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA
Kauke-Navarro M, Knoedler S, Panayi AC, Knoedler L, Noel OF, Pomahac B. Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA. Transplantation 2022, 107: 86-97. PMID: 36210500, DOI: 10.1097/tp.0000000000004342.Peer-Reviewed Original ResearchMeSH KeywordsGraft RejectionImmune TolerancePrecision MedicineT-Lymphocytes, RegulatoryVascularized Composite AllotransplantationConceptsSolid organ transplantationOrgan transplantationSide effectsField of VCAMedication side effectsBeneficial clinical effectsChimeric antigen receptorSevere side effectsRisk of infectionT cell receptorMaintenance immunosupressionMetabolic complicationsClinical effectsTransplant rejectionLifelong immunosuppressionImmune cellsTregsComposite allotransplantationSpecific antigenTherapeutic efficacyAntigen receptorStable levelPrecision medicineImmune system mechanismsImmunotolerance
2021
A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models
Kauke M, Safi AF, Panayi AC, Palmer WJ, Haug V, Kollar B, Nelms L, Tchiloemba B, Pomahac B. A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models. Journal Of Plastic Reconstructive & Aesthetic Surgery 2021, 75: 586-604. PMID: 34895853, DOI: 10.1016/j.bjps.2021.11.003.Peer-Reviewed Original ResearchConceptsSystematic reviewImmunomodulatory strategiesPreclinical researchAvailable immunosuppressive regimensCurrent standard regimenSystemic side effectsDrug-based approachesMeta-Analyses (PRISMA) guidelinesVCA modelPreferred Reporting ItemsHind limb modelNovel immunomodulatoryRejection episodesAcute rejectionImmunosuppressive regimensStandard regimenAllograft acceptanceAlloimmune responseSuppression therapyImmunomodulation strategiesLimb transplantsPreclinical modelsRat modelHuman trialsTherapeutic approachesLong-term Outcomes After Facial Allotransplantation: Systematic Review of the Literature
Tchiloemba B, Kauke M, Haug V, Abdulrazzak O, Safi AF, Kollar B, Pomahac B. Long-term Outcomes After Facial Allotransplantation: Systematic Review of the Literature. Transplantation 2021, 105: 1869-1880. PMID: 33148976, DOI: 10.1097/tp.0000000000003513.Peer-Reviewed Original ResearchConceptsSystematic reviewAcute cell-mediated rejectionPositive risk-benefit ratioRecurrent acute rejection episodesLong-term outcome dataAcute rejection episodesChronic vascular rejectionFirst year posttransplantImmunosuppression-related complicationsCell-mediated rejectionSingle-center experiencePubMed/MEDLINE databaseLong-term outcomesRisk-benefit ratioEnglish full-text articlesQuality of lifeFull-text articlesAcute rejectionAllograft lossChronic rejectionRejection episodesVascular rejectionInfectious complicationsInfectious episodesMetabolic complicationsDynamic Maxillary Sinus Changes of Facial Vascularized Composite Allotransplants.
Kauke M, Safi AF, Palmer WJ, Kollar B, Nelms L, Tchiloemba B, Haug V, Pomahac B. Dynamic Maxillary Sinus Changes of Facial Vascularized Composite Allotransplants. Plastic & Reconstructive Surgery 2021, 147: 722-727. PMID: 33620943, DOI: 10.1097/prs.0000000000007673.Peer-Reviewed Original ResearchConceptsMaxillary sinusFace transplant recipientsTransplant recipientsAllograft rejectionTissue changesBiopsy-proven allograft rejectionDiagnosis of rejectionMedication side effectsMaxillary sinus mucosaIndividualized treatment strategiesTissue allograft rejectionVascularized composite allotransplantsFace transplant patientsDynamic tissue changesRadiologic biomarkersRejection gradeTransplant patientsMucosal swellingSinonasal tractSinus changesSinus mucosaClinical managementTomographic scanPathologic changesTreatment strategies
2020
Pathologies of oral and sinonasal mucosa following facial vascularized composite allotransplantation
Kauke-Navarro M, Tchiloemba B, Haug V, Kollar B, Diehm Y, Safi AF, Treister NS, Annino DJ, Marty FM, Lian CG, Murphy GF, Pomahac B. Pathologies of oral and sinonasal mucosa following facial vascularized composite allotransplantation. Journal Of Plastic Reconstructive & Aesthetic Surgery 2020, 74: 1562-1571. PMID: 33376080, DOI: 10.1016/j.bjps.2020.11.028.Peer-Reviewed Original ResearchConceptsNasal mucous membraneMucous membranesMucosal inflammationMucosal lesionsBanff gradeInflammatory mucosal lesionsUlceration/erosionRetrospective cohort studyClinico-pathologic variablesMucosal rejectionCohort studyCutaneous changesIndependent predictorsMucosal assessmentOral lesionsSkin rejectionSinonasal mucosaCommon lesionsMedical recordsUnivariate analysisCutaneous pathologyBuccal mucosaNasal vestibuleOral cavityComposite allotransplantationLocal immunosuppression in vascularized composite allotransplantation (VCA): A systematic review
Safi AF, Kauke M, Nelms L, Palmer WJ, Tchiloemba B, Kollar B, Haug V, Pomahač B. Local immunosuppression in vascularized composite allotransplantation (VCA): A systematic review. Journal Of Plastic Reconstructive & Aesthetic Surgery 2020, 74: 327-335. PMID: 33229219, DOI: 10.1016/j.bjps.2020.10.003.Peer-Reviewed Original ResearchConceptsLocal immunosuppressionSystematic reviewAllograft survivalComposite allotransplantationAllograft survival dataCell-based therapy strategiesImproved allograft survivalMain immunosuppressive agentMeta-Analyses (PRISMA) guidelinesPreclinical animal studiesPreferred Reporting ItemsMalignant side effectsImmunosuppressive agentsPreclinical dataSignificant prolongationRat modelHuman trialsExclusion criteriaImmunosuppressionSide effectsAnimal studiesReporting ItemsPubMed databaseSystemic toxicityTherapy strategiesMucosa and Rejection in Facial Vascularized Composite Allotransplantation: A Systematic Review.
Kauke M, Safi AF, Zhegibe A, Haug V, Kollar B, Nelms L, Palmer WJ, Tchiloemba B, Lian CG, Murphy GF, Pomahac B. Mucosa and Rejection in Facial Vascularized Composite Allotransplantation: A Systematic Review. Transplantation 2020, 104: 2616-2624. PMID: 32053572, DOI: 10.1097/tp.0000000000003171.Peer-Reviewed Original ResearchConceptsMucosal rejectionSystematic reviewRejection gradeMucosal biopsiesPatient managementComposite allotransplantationDiagnosis of rejectionFunction of patientsFacial Vascularized Composite AllotransplantationMeta-Analyses (PRISMA) guidelinesMEDLINE/PubMedPreferred Reporting ItemsVascularized Composite AllotransplantationPosttransplant periodBiopsy gradeSkin rejectionMucosa biopsiesAllograft skinAnimal studiesReporting ItemsBiopsyRejection processFacial allotransplantsMucosaTarget tissues
2019
MMP3 Is a Non-invasive Biomarker of Rejection in Skin-Bearing Vascularized Composite Allotransplantation: A Multicenter Validation Study
Kollar B, Uffing A, Borges TJ, Shubin AV, Aoyama BT, Dagot C, Haug V, Kauke M, Safi AF, Talbot SG, Morelon E, Dakpe S, Pomahac B, Riella LV. MMP3 Is a Non-invasive Biomarker of Rejection in Skin-Bearing Vascularized Composite Allotransplantation: A Multicenter Validation Study. Frontiers In Immunology 2019, 10: 2771. PMID: 31849957, PMCID: PMC6897344, DOI: 10.3389/fimmu.2019.02771.Peer-Reviewed Original ResearchConceptsMatrix metalloproteinase-3MMP3 levelsNon-invasive biomarkersTransplant recipientsAcute rejectionHealthy controlsComposite allotransplantationRejection stateCandidate non-invasive biomarkersUpper extremity transplant recipientsSerum samplesAntibody-mediated rejectionKidney transplant recipientsSeverity of rejectionPre-transplant levelsAutoimmune skin diseaseLongitudinal serum samplesSkin disease patientsVascularized Composite AllotransplantationMulticenter validation studyFace transplant recipientsLarger validation studiesClinical VCARejection episodesVCA patients